Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 15

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Inherent Immunogenicity or Lack Thereof of Pluripotent Stem Cells: Implications for Cell Replacement Therapy

Chhabra, Arvind · 2017 · Frontiers in Immunology

Abstract

Donor-specific induced pluripotent stem cells (iPSCs) offer opportunities for personalized cell replacement therapeutic approaches due to their unlimited self-renewal potential and ability to differentiate into different somatic cells. A significant progress has been made toward generating iPSC lines that are free of integrating viral vectors, development of xeno-free culture conditions, and differentiation of pluripotent stem cells (PSCs) into functional somatic cell lineages. Since donor-specific iPSC lines are genetically identical to the individual, they are expected to be immunologically matched and these iPSC lines and their cellular derivatives are not expected to be immunologically rejected. However, studies in mouse models, utilizing rejection of teratomas as a model, have claimed that syngenic iPSC lines, especially the iPSC lines derived with integrating viral vectors, could be inherently immunogenic. This manuscript reviews current understanding of inherent immunogenicity of PSC lines, especially that of the human iPSC lines and their cellular derivatives, and strategies to overcome it.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2017.00993

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 66

  1. Thomson, 1998, Embryonic stem cell lines derived from human blastocysts, Science, 282, 1145, 10.1126/science.282.5391.1145 · DOI · Paper page
  2. Takahashi, 2006, Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors, Cell, 126, 663, 10.1016/j.cell.2006.07.024 · DOI · Paper page
  3. Takahashi, 2007, Induction of pluripotent stem cells from adult human fibroblasts by defined factors, Cell, 131, 861, 10.1016/j.cell.2007.11.019 · DOI · Paper page
  4. Yu, 2007, Induced pluripotent stem cell lines derived from human somatic cells, Science, 318, 1917, 10.1126/science.1151526 · DOI · Paper page
  5. Zhao, 2011, Immunogenicity of induced pluripotent stem cells, Nature, 474, 212, 10.1038/nature10135 · DOI · Paper page
  6. Okita, 2011, Immunogenicity of induced pluripotent stem cells, Circ Res, 109, 720, 10.1161/RES.0b013e318232e187 · DOI
  7. Araki, 2013, Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells, Nature, 494, 100, 10.1038/nature11807 · DOI · Paper page
  8. Todorova, 2016, Brief report: immune microenvironment determines the immunogenicity of induced pluripotent stem cell derivatives, Stem Cells, 34, 510, 10.1002/stem.2227 · DOI
  9. Zhao, 2015, Humanized mice reveal differential immunogenicity of cells derived from autologous induced pluripotent stem cells, Cell Stem Cell, 17, 353, 10.1016/j.stem.2015.07.021 · DOI · Paper page
  10. de Almeida, 2014, Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance, Nat Commun, 5, 3903, 10.1038/ncomms4903 · DOI · Paper page
  11. Koch, 2008, Immunosuppression by embryonic stem cells, Stem Cells, 26, 89, 10.1634/stemcells.2007-0151 · DOI
  12. Li, 2004, Human embryonic stem cells possess immune-privileged properties, Stem Cells, 22, 448, 10.1634/stemcells.22-4-448 · DOI · Paper page
  13. Chhabra, 2017, Human dendritic cell-derived induced pluripotent stem cell lines are not immunogenic, J Immunol, 198, 1875, 10.4049/jimmunol.1601676 · DOI
  14. Magliocca, 2006, Undifferentiated murine embryonic stem cells cannot induce portal tolerance but may possess immune privilege secondary to reduced major histocompatibility complex antigen expression, Stem Cells Dev, 15, 707, 10.1089/scd.2006.15.707 · doi:10.1089/scd.2006.15.707
  15. Dressel, 2010, Pluripotent stem cells are highly susceptible targets for syngeneic, allogeneic, and xenogeneic natural killer cells, FASEB J, 24, 2164, 10.1096/fj.09-134957 · DOI
  16. Kim, 2010, Epigenetic memory in induced pluripotent stem cells, Nature, 467, 285, 10.1038/nature09342 · DOI · Paper page
  17. Vaskova, 2013, “Epigenetic memory” phenomenon in induced pluripotent stem cells, Acta Naturae, 5, 15, 10.32607/20758251-2013-5-4-15-21 · DOI
  18. Schnerch, 2010, Distinguishing between mouse and human pluripotent stem cell regulation: the best laid plans of mice and men, Stem Cells, 28, 419, 10.1002/stem.298 · DOI
  19. Ginis, 2004, Differences between human and mouse embryonic stem cells, Dev Biol, 269, 360, 10.1016/j.ydbio.2003.12.034 · DOI · Paper page
  20. Suh, 2004, Human embryonic stem cells express a unique set of microRNAs, Dev Biol, 270, 488, 10.1016/j.ydbio.2004.02.019 · DOI · Paper page
  21. Mestas, 2004, Of mice and not men: differences between mouse and human immunology, J Immunol, 172, 2731, 10.4049/jimmunol.172.5.2731 · DOI · Paper page
  22. Sitnicka, 2003, Human CD34+ hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3: distinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells, Blood, 102, 881, 10.1182/blood-2002-06-1694 · DOI
  23. Tokugawa, 1997, A molecular basis for species differences in Thy-1 expression patterns, Mol Immunol, 34, 1263, 10.1016/S0161-5890(98)00010-8 · DOI
  24. Peschon, 1994, Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice, J Exp Med, 180, 1955, 10.1084/jem.180.5.1955 · DOI · Paper page
  25. Elder, 2001, Distinct T cell developmental consequences in humans and mice expressing identical mutations in the DLAARN motif of ZAP-70, J Immunol, 166, 656, 10.4049/jimmunol.166.1.656 · DOI
  26. Tibbetts, 2003, The death effector domain protein family: regulators of cellular homeostasis, Nat Immunol, 4, 404, 10.1038/ni0503-404 · DOI · Paper page
  27. Chun, 2002, Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency, Nature, 419, 395, 10.1038/nature01063 · DOI · Paper page
  28. Lublin, 1993, Monoclonal anti-gamma interferon antibodies enhance experimental allergic encephalomyelitis, Autoimmunity, 16, 267, 10.3109/08916939309014645 · DOI
  29. Drukker, 2004, Immunogenicity of human embryonic stem cells: can we achieve tolerance?, Springer Semin Immunopathol, 26, 201, 10.1007/s00281-004-0163-5 · DOI
  30. Segall, 1996, Generation of primary antigen-specific human cytotoxic T lymphocytes in human/mouse radiation chimera, Blood, 88, 721, 10.1182/blood.V88.2.721.bloodjournal882721 · DOI
  31. Mohib, 2010, Human embryonic stem cell-extracts inhibit the differentiation and function of monocyte-derived dendritic cells, Stem Cell Rev, 6, 611, 10.1007/s12015-010-9185-7 · DOI
  32. Yachimovich-Cohen, 2010, Human embryonic stem cells suppress T cell responses via arginase I-dependent mechanism, J Immunol, 184, 1300, 10.4049/jimmunol.0804261 · DOI
  33. Rong, 2014, An effective approach to prevent immune rejection of human ESC-derived allografts, Cell Stem Cell, 14, 121, 10.1016/j.stem.2013.11.014 · DOI · Paper page
  34. Schuurhuis, 2006, Ins and outs of dendritic cells, Int Arch Allergy Immunol, 140, 53, 10.1159/000092002 · DOI
  35. Merad, 2013, The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting, Annu Rev Immunol, 31, 563, 10.1146/annurev-immunol-020711-074950 · DOI · Paper page
  36. Steinman, 2012, Decisions about dendritic cells: past, present, and future, Annu Rev Immunol, 30, 1, 10.1146/annurev-immunol-100311-102839 · DOI · Paper page
  37. Drukker, 2002, Characterization of the expression of MHC proteins in human embryonic stem cells, Proc Natl Acad Sci U S A, 99, 9864, 10.1073/pnas.142298299 · DOI · Paper page
  38. Lu, 2014, Negligible immunogenicity of induced pluripotent stem cells derived from human skin fibroblasts, PLoS One, 9, e114949, 10.1371/journal.pone.0114949 · DOI
  39. Morizane, 2013, Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate, Stem Cell Reports, 1, 283, 10.1016/j.stemcr.2013.08.007 · DOI · Paper page
  40. Koch, 2006, Complement-dependent control of teratoma formation by embryonic stem cells, J Immunol, 177, 4803, 10.4049/jimmunol.177.7.4803 · doi:10.4049/jimmunol.177.7.4803
  41. Albert, 1998, Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs, Nature, 392, 86, 10.1038/32183 · DOI · Paper page
  42. Kreisel, 2002, Non-hematopoietic allograft cells directly activate CD8+ T cells and trigger acute rejection: an alternative mechanism of allorecognition, Nat Med, 8, 233, 10.1038/nm0302-233 · DOI · Paper page
  43. Swijnenburg, 2008, Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts, Proc Natl Acad Sci U S A, 105, 12991, 10.1073/pnas.0805802105 · DOI · Paper page
  44. Pearl, 2011, Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells, Cell Stem Cell, 8, 309, 10.1016/j.stem.2011.01.012 · DOI · Paper page
  45. Gibbons, 2008, Manipulating the immune system for anti-tumor responses and transplant tolerance via mixed hematopoietic chimerism, Immunol Rev, 223, 334, 10.1111/j.1600-065X.2008.00636.x · DOI
  46. Waldmann, 2006, Regulatory T cells in transplantation, Semin Immunol, 18, 111, 10.1016/j.smim.2006.01.010 · DOI
  47. Chhabra, 2008, CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model, J Immunol, 181, 1063, 10.4049/jimmunol.181.2.1063 · DOI
  48. Mukherji, 1995, Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells, Proc Natl Acad Sci U S A, 92, 8078, 10.1073/pnas.92.17.8078 · DOI · Paper page
  49. Dudley, 2002, Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes, Science, 298, 850, 10.1126/science.1076514 · DOI · Paper page
  50. Morgan, 2006, Cancer regression in patients after transfer of genetically engineered lymphocytes, Science, 314, 126, 10.1126/science.1129003 · DOI · Paper page
  51. Gilboa, 2007, DC-based cancer vaccines, J Clin Invest, 117, 1195, 10.1172/JCI31205 · DOI · Paper page
  52. Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci Transl Med, 3, 95ra73, 10.1126/scitranslmed.3002842 · DOI · Paper page
  53. Chhabra, 2011, TCR-engineered, customized, antitumor T cells for cancer immunotherapy: advantages and limitations, ScientificWorldJournal, 11, 121, 10.1100/tsw.2011.10 · DOI
  54. Rosenberg, 2004, Cancer immunotherapy: moving beyond current vaccines, Nat Med, 10, 909, 10.1038/nm1100 · DOI · Paper page
  55. Ray, 2009, Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma, Clin Dermatol, 27, 603, 10.1016/j.clindermatol.2008.09.019 · doi:10.1016/j.clindermatol.2008.09.019
  56. Chhabra, 2008, Silencing of endogenous IL-10 in human dendritic cells leads to the generation of an improved CTL response against human melanoma associated antigenic epitope, MART-1 27-35, Clin Immunol, 126, 251, 10.1016/j.clim.2007.11.011 · DOI
  57. Zhan, 2004, Functional antigen-presenting leucocytes derived from human embryonic stem cells in vitro, Lancet, 364, 163, 10.1016/S0140-6736(04)16629-4 · DOI · Paper page
  58. Woll, 2009, Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity, Blood, 113, 6094, 10.1182/blood-2008-06-165225 · DOI · Paper page
  59. Slukvin, 2006, Directed differentiation of human embryonic stem cells into functional dendritic cells through the myeloid pathway, J Immunol, 176, 2924, 10.4049/jimmunol.176.5.2924 · DOI
  60. Galic, 2006, T lineage differentiation from human embryonic stem cells, Proc Natl Acad Sci U S A, 103, 11742, 10.1073/pnas.0604244103 · DOI
  61. Tseng, 2009, Generation of immunogenic dendritic cells from human embryonic stem cells without serum and feeder cells, Regen Med, 4, 513, 10.2217/rme.09.25 · doi:10.2217/rme.09.25
  62. Silk, 2012, Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141(+)XCR1+ dendritic cells, Gene Ther, 19, 1035, 10.1038/gt.2011.177 · doi:10.1038/gt.2011.177
  63. Themeli, 2013, Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy, Nat Biotechnol, 31, 928, 10.1038/nbt.2678 · DOI · Paper page
  64. Nishimura, 2013, Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation, Cell Stem Cell, 12, 114, 10.1016/j.stem.2012.11.002 · DOI · Paper page
  65. Vizcardo, 2013, Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells, Cell Stem Cell, 12, 31, 10.1016/j.stem.2012.12.006 · DOI · Paper page
  66. Knorr, 2010, Pluripotent stem cell-derived natural killer cells for cancer therapy, Transl Res, 156, 147, 10.1016/j.trsl.2010.07.008 · DOI

Metadata

Authors
Chhabra, A.
Venue
Frontiers in Immunology
Published
2017-08-18
Volume
8
ISSN
1664-3224
Cited by
15
References
5
Funders
Connecticut Innovations (10-SCA-23 and 12-SCB-05)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inherent Immunogenicity or Lack Thereof of Pluripotent Stem Cells: Implications for Cell Replacement Therapy. https://app.cochat.ai/papers/10.3389/fimmu.2017.00993
The paper
Chhabra, A. (2017). Inherent Immunogenicity or Lack Thereof of Pluripotent Stem Cells: Implications for Cell Replacement Therapy. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2017.00993

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.